Sofinnova raises 1.2 billion euros to fuel the next wave of life sciences innovation

Leading European venture capital firm Sofinnova Partners today announced it has raised 1.2 billion euros ($1.25 billion) across its platform of investment strategies over the past year, including more than 1 billion euros secured in the last quarter.

Sofinnova said this achievement brings the firm’s assets under management (AUM) to more than 4 billion euros, solidifying its position as a leading backer of transformative innovation in healthcare and sustainability. Further details on individual funds will be disclosed upon their final closings.

“All seven of Sofinnova’s investment strategies - from incubation to later-stage growth, spanning biotech, medtech, industrial biotech and digital medicine - have capital to back the next generation of life sciences companies,” said Antoine Papiernik, chairman and managing partner of Sofinnova, noting that, “with the new funds, we anticipate supporting 50 to 60 new companies, empowering a new wave of entrepreneurs tackling some of the world’s most pressing health and sustainability challenges.”